AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

AbbVie’s two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing ... while those of competitor Bristol Myers ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Leerink analyst David Risinger upgraded Bristol Myers (BMY) to Outperform from Market Perform with a price target of $73, up from $55. The firm expects “upward pressure” on Cobenfy and milvexian ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...

AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie ABBV said that its Phase 2 trial ...